Naturally Inspired | Scientifically Defined

Specialist in plant derived cell signalling small molecules to address
challenging medical conditions for humans and companion animals

QBiotics announces clinical collaboration with MSD targeting unresectable melanoma

13 August 2020

  • MSD collaboration to investigate QBiotics’ lead molecule tigilanol tiglate in combination with KEYTRUDA® (pembrolizumab)
  • Tigilanol tiglate is a novel, small molecule that is being developed as an intratumoural treatment for solid tumours
  • Melanoma is the second human application being pursued for tigilanol tiglate, following on from the Company’s ongoing Phase I/II study in head and neck squamous cell carcinoma.


PDF documentRead the full announcement